---
document_datetime: 2025-12-02 04:53:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord.html
document_name: vildagliptin-metformin-hydrochloride-accord.html
version: success
processing_time: 0.1236466
conversion_datetime: 2025-12-25 11:30:11.659785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vildagliptin / Metformin hydrochloride Accord

[RSS](/en/individual-human-medicine.xml/67528)

##### Authorised

This medicine is authorised for use in the European Union

vildagliptin / metformin hydrochloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vildagliptin / Metformin hydrochloride Accord](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78394)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vildagliptin/Metformin hydrochloride Accord is a diabetes medicine that is used in addition to diet and exercise to improve control of blood glucose (sugar) levels in adults with type 2 diabetes. It is used:

- in patients whose blood glucose levels are not adequately controlled by metformin alone;
- in patients who are already taking a combination of vildagliptin and metformin as separate tablets;
- together with other diabetes medicines, including insulin, when these medicines do not provide adequate control of blood glucose.

Vildagliptin/Metformin hydrochloride Accord is a 'generic medicine'. This means that it contains the same active substances and works in the same way as a 'reference medicine' already authorised in the EU called Eucreas.

Vildagliptin/Metformin hydrochloride Accord contains the active substances vildagliptin and metformin hydrochloride.

Expand section

Collapse section

## How is Vildagliptin/Metformin hydrochloride Accord used?

Vildagliptin/Metformin hydrochloride Accord is available as tablets and the recommended dose is one tablet twice a day (one in the morning and one in the evening). The starting tablet strength depends on the patient's current treatment and the expected effects of Vildagliptin/Metformin hydrochloride Accord. Taking Vildagliptin/Metformin hydrochloride Accord with or just after food may reduce any stomach problems caused by metformin.

The doctor should carry out tests to check the patient's kidney and liver function before treatment with Vildagliptin/Metformin hydrochloride Accord and at regular intervals during treatment.

The medicine can only be obtained with a prescription. For more information about using Vildagliptin/Metformin hydrochloride Accord, see the [package leaflet](/en/node/43212) or contact your doctor or pharmacist.

## How does Vildagliptin/Metformin hydrochloride Accord work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the glucose level in the blood or the body is unable to use insulin effectively. Vildagliptin/Metformin hydrochloride Accord contains two [active substances](/en/node/43123) , each with a different mode of action.

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by blocking the breakdown of incretin hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By blocking the breakdown of incretin hormones in the blood, vildagliptin prolongs their action, stimulating the pancreas to produce more insulin when blood glucose levels are high. Vildagliptin does not work when the blood glucose is low. Vildagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.

Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. As a result of the action of both substances, the blood glucose is reduced, which helps to control type 2 diabetes.

## How has Vildagliptin/Metformin hydrochloride Accord been studied?

Studies on the benefits and risks of the active substances in the authorised use have already been carried out with the reference medicine, Eucreas, and do not need to be repeated for Vildagliptin/Metformin hydrochloride Accord.

As for every medicine, the company provided studies on the quality of Vildagliptin/Metformin hydrochloride Accord. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Vildagliptin/Metformin hydrochloride Accord?

Because Vildagliptin/Metformin hydrochloride Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Vildagliptin/Metformin hydrochloride Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Vildagliptin/Metformin hydrochloride Accord has been shown to have comparable quality and to be bioequivalent to Eucreas. Therefore, the Agency's view was that, as for Eucreas, the benefits of Vildagliptin/Metformin hydrochloride Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vildagliptin/Metformin hydrochloride Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vildagliptin/Metformin hydrochloride Accord have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vildagliptin/Metformin hydrochloride Accord are continuously monitored. Suspected side effects reported with Vildagliptin/Metformin hydrochloride Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vildagliptin/Metformin hydrochloride Accord

Vildagliptin/Metformin hydrochloride Accord received a marketing authorisation valid throughout the EU on 24 March 2022.

Vildagliptin / Metformin hydrochloride Accord : EPAR - Medicine Overview

Reference Number: EMA/197889/2022

English (EN) (169.66 KB - PDF)

**First published:** 17/06/2022

[View](/en/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-253)

български (BG) (195.45 KB - PDF)

**First published:**

17/06/2022

[View](/bg/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_bg.pdf)

español (ES) (170.24 KB - PDF)

**First published:**

17/06/2022

[View](/es/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_es.pdf)

čeština (CS) (191.22 KB - PDF)

**First published:**

17/06/2022

[View](/cs/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (161.18 KB - PDF)

**First published:**

17/06/2022

[View](/da/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (172.9 KB - PDF)

**First published:**

17/06/2022

[View](/de/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (159.64 KB - PDF)

**First published:**

17/06/2022

[View](/et/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (197.37 KB - PDF)

**First published:**

17/06/2022

[View](/el/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_el.pdf)

français (FR) (170.62 KB - PDF)

**First published:**

17/06/2022

[View](/fr/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (188.62 KB - PDF)

**First published:**

17/06/2022

[View](/hr/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (169.58 KB - PDF)

**First published:**

17/06/2022

[View](/it/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (212.97 KB - PDF)

**First published:**

17/06/2022

[View](/lv/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (192.09 KB - PDF)

**First published:**

17/06/2022

[View](/lt/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (190.99 KB - PDF)

**First published:**

17/06/2022

[View](/hu/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (194.97 KB - PDF)

**First published:**

17/06/2022

[View](/mt/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (170.05 KB - PDF)

**First published:**

17/06/2022

[View](/nl/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_nl.pdf)

polski (PL) (194.49 KB - PDF)

**First published:**

17/06/2022

[View](/pl/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_pl.pdf)

português (PT) (170.59 KB - PDF)

**First published:**

17/06/2022

[View](/pt/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_pt.pdf)

română (RO) (192.17 KB - PDF)

**First published:**

17/06/2022

[View](/ro/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (184.85 KB - PDF)

**First published:**

17/06/2022

[View](/sk/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (187.47 KB - PDF)

**First published:**

17/06/2022

[View](/sl/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (167.28 KB - PDF)

**First published:**

17/06/2022

[View](/fi/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (167.64 KB - PDF)

**First published:**

17/06/2022

[View](/sv/documents/overview/vildagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sv.pdf)

Vildagliptin / Metformin hydrochloride Accord : EPAR - Risk management plan summary

English (EN) (107.94 KB - PDF)

**First published:** 17/06/2022

[View](/en/documents/rmp-summary/vildagliptin-metformin-hydrochloride-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Vildagliptin / Metformin hydrochloride Accord : EPAR - Product Information

English (EN) (436.8 KB - PDF)

**First published:** 17/06/2022

**Last updated:** 25/07/2025

[View](/en/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-832)

български (BG) (643.29 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/bg/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_bg.pdf)

español (ES) (531.73 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/es/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_es.pdf)

čeština (CS) (608.46 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/cs/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_cs.pdf)

dansk (DA) (587.47 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/da/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_da.pdf)

Deutsch (DE) (586.28 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/de/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_de.pdf)

eesti keel (ET) (499.48 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/et/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_et.pdf)

ελληνικά (EL) (659.89 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/el/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_el.pdf)

français (FR) (594.46 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/fr/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_fr.pdf)

hrvatski (HR) (555.96 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/hr/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_hr.pdf)

íslenska (IS) (513.72 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/is/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_is.pdf)

italiano (IT) (611.37 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/it/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (573.88 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/lv/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (571.45 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/lt/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_lt.pdf)

magyar (HU) (608.95 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/hu/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_hu.pdf)

Malti (MT) (657.45 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/mt/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_mt.pdf)

Nederlands (NL) (512.11 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/nl/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_nl.pdf)

norsk (NO) (590.12 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/no/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_no.pdf)

polski (PL) (595.29 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/pl/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_pl.pdf)

português (PT) (556.04 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/pt/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_pt.pdf)

română (RO) (600.64 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/ro/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_ro.pdf)

slovenčina (SK) (544.38 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/sk/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_sk.pdf)

slovenščina (SL) (578.96 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/sl/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_sl.pdf)

Suomi (FI) (540.04 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/fi/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_fi.pdf)

svenska (SV) (527.12 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

25/07/2025

[View](/sv/documents/product-information/vildagliptin-metformin-hydrochloride-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287822 25/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vildagliptin / Metformin hydrochloride Accord : EPAR - All authorised presentations

English (EN) (89.81 KB - PDF)

**First published:** 17/06/2022

**Last updated:** 05/10/2022

[View](/en/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-692)

български (BG) (93.91 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/bg/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (89.22 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/es/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (91.23 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/cs/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.59 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/da/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (90.96 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/de/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (88.88 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/et/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (95.23 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/el/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (90.4 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/fr/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (90.58 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/hr/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (90.93 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/is/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (88.91 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/it/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (92.39 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/lv/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (92.86 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/lt/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (91.56 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/hu/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (91.93 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/mt/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (88.83 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/nl/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (90.83 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/no/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (90.6 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/pl/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (90.1 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/pt/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (90.51 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/ro/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (92.24 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/sk/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (90.49 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/sl/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (88.97 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/fi/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (89.48 KB - PDF)

**First published:**

17/06/2022

**Last updated:**

05/10/2022

[View](/sv/documents/all-authorised-presentations/vildagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vildagliptin / Metformin hydrochloride Accord Active substance

- metformin hydrochloride
- vildagliptin

International non-proprietary name (INN) or common name

- vildagliptin
- metformin hydrochloride

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD08

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:

- in patients who are inadequately controlled with metformin hydrochloride alone.
- in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

## Authorisation details

EMA product number EMEA/H/C/005738

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 16/12/2021 Marketing authorisation issued 24/03/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vildagliptin / Metformin hydrochloride Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (236.42 KB - PDF)

**First published:** 04/04/2025

**Last updated:** 25/07/2025

[View](/en/documents/procedural-steps-after/vildagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vildagliptin / Metformin hydrochloride Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (139.4 KB - PDF)

**First published:** 05/10/2022

**Last updated:** 04/04/2025

[View](/en/documents/procedural-steps-after/vildagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Vildagliptin / Metformin hydrochloride Accord : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/246681/2022

English (EN) (963.32 KB - PDF)

**First published:** 17/06/2022

[View](/en/documents/assessment-report/vildagliptin-metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vildagliptin/Metformin hydrochloride Accord

Adopted

Reference Number: EMA/CHMP/687405/2021

English (EN) (147.26 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vildagliptinmetformin-hydrochloride-accord_en.pdf)

#### News on Vildagliptin / Metformin hydrochloride Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Vildagliptin/Metformin hydrochloride Accord : EPAR - Product information - tracked changes

English (EN) (126.32 KB - DOCX)

**First published:** 25/07/2025

[View](/en/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-917)

български (BG) (155.65 KB - DOCX)

**First published:**

25/07/2025

[View](/bg/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (131.39 KB - DOCX)

**First published:**

25/07/2025

[View](/es/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (123.59 KB - DOCX)

**First published:**

25/07/2025

[View](/cs/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (129.69 KB - DOCX)

**First published:**

25/07/2025

[View](/da/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (134.05 KB - DOCX)

**First published:**

25/07/2025

[View](/de/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (112.51 KB - DOCX)

**First published:**

25/07/2025

[View](/et/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (158.95 KB - DOCX)

**First published:**

25/07/2025

[View](/el/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (143.56 KB - DOCX)

**First published:**

25/07/2025

[View](/fr/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (138.71 KB - DOCX)

**First published:**

25/07/2025

[View](/hr/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (119.87 KB - DOCX)

**First published:**

25/07/2025

[View](/is/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (152.41 KB - DOCX)

**First published:**

25/07/2025

[View](/it/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (138.5 KB - DOCX)

**First published:**

25/07/2025

[View](/lv/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (112.47 KB - DOCX)

**First published:**

25/07/2025

[View](/lt/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (138.17 KB - DOCX)

**First published:**

25/07/2025

[View](/hu/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (134.19 KB - DOCX)

**First published:**

25/07/2025

[View](/mt/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (126.49 KB - DOCX)

**First published:**

25/07/2025

[View](/nl/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (124.98 KB - DOCX)

**First published:**

25/07/2025

[View](/no/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (130.74 KB - DOCX)

**First published:**

25/07/2025

[View](/pl/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (132.42 KB - DOCX)

**First published:**

25/07/2025

[View](/pt/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (139.15 KB - DOCX)

**First published:**

25/07/2025

[View](/ro/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (122.19 KB - DOCX)

**First published:**

25/07/2025

[View](/sk/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (137.62 KB - DOCX)

**First published:**

25/07/2025

[View](/sl/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (116.4 KB - DOCX)

**First published:**

25/07/2025

[View](/fi/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (129.42 KB - DOCX)

**First published:**

25/07/2025

[View](/sv/documents/product-information-tracked-changes/vildagliptin-metformin-hydrochloride-accord-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 25/07/2025

## Share this page

[Back to top](#main-content)